Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals

Bloomberg2021-10-23

(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to people familiar with the matter. The New ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

YTigger
2021-10-24
YTigger
Up
- pokokoko:
  up
LimHianYew
2021-10-24
LimHianYew
Good
LerLer
2021-10-24
LerLer
Like
- LimHianYew:
  Done
- JooL:
  😄
supergrowth
2021-10-24
supergrowth
Good dividend. Withholding tax is reduce dividend☹
Victorhc88
2021-10-24
Victorhc88
Like pls
ivy888
2021-10-24
ivy888
Like
- supergrowth:
  ok

发表看法

881

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2177414750?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-23 10:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2177414750","market":"us","top_or_hot":-1,"title":"Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals","media":"Bloomberg","content":"<div>\n<p>(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to people familiar with the matter.\nThe New ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html\">网页链接</a>\n\n</div>\n","source":"lsy1584095487587","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-23 10:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to people familiar with the matter.\nThe New ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AUPH","symbol_name":"Aurinia Pharmaceuticals Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html","article_id":"2177414750","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2177414750","pubTimestamp":1634955009,"sourceInfo":{"source_id":"lsy1584095487587","name":"Bloomberg"},"weMediaInfo":null,"summary":"(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmac","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AUPH":"Aurinia Pharmaceuticals Inc","BMY":"施贵宝"},"translate_title":"百时美收购Aurinia制药公司","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUPH":0.9,"BMY":0.9},"content_text":"(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to people familiar with the matter.\nThe New York-based company recently approached Aurinia about a deal, said the people, who asked to not be identified because the matter isn’t public. No final decision has been made and Bristol-Myers could opt against any potential deal, they said.\nAurinia rose 27% to close at $28.00 in New York on Friday, giving the company a market value of about $3.6 billion.\nA spokesperson for Bristol Myers said the company wouldn’t comment on rumors. A representative for Aurinia declined to comment.\nFormally known as Isotechnika Pharma, Aurinia specializes in therapies for severe autoimmune diseases, according to its website. It recently introduced an oral therapy for adults with lupus nephritis, a kidney disorder.\nThe talks come during a boom in health-care dealmaking, as large pharma companies look to broaden their suite of therapies via acquisitions. Bristol-Myers is planning to tender its shares in Acceleron Pharma Inc. after Merck & Co. agreed to buy the biotechnology company for $11.5 billion, Bloomberg News reported this week.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":858558559,"gmtCreate":1635088754347,"gmtModify":1635088812498,"author":{"id":"3585473797689026","authorId":"3585473797689026","name":"YTigger","avatar":"https://static.tigerbbs.com/eaefeca0a5a25faa930c0d98718014bc","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3585473797689026","idStr":"3585473797689026"},"htmlText":"Up","listText":"Up","text":"Up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/858558559","repostId":2177414750,"repostType":4,"repost":{"id":"2177414750","pubTimestamp":1634955009,"share":"https://www.laohu8.com/m/news/2177414750?lang=&edition=full","pubTime":"2021-10-23 10:10","market":"us","language":"en","title":"Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2177414750","media":"Bloomberg","summary":"(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmac","content":"<p>(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm <a href=\"https://laohu8.com/S/AUPH\">Aurinia Pharmaceuticals Inc</a>., according to people familiar with the matter.</p>\n<p>The New York-based company recently approached Aurinia about a deal, said the people, who asked to not be identified because the matter isn’t public. No final decision has been made and Bristol-Myers could opt against any potential deal, they said.</p>\n<p>Aurinia rose 27% to close at $28.00 in New York on Friday, giving the company a market value of about $3.6 billion.</p>\n<p>A spokesperson for Bristol Myers said the company wouldn’t comment on rumors. A representative for Aurinia declined to comment.</p>\n<p>Formally known as Isotechnika Pharma, Aurinia specializes in therapies for severe autoimmune diseases, according to its website. It recently introduced an oral therapy for adults with lupus nephritis, a kidney disorder.</p>\n<p>The talks come during a boom in health-care dealmaking, as large pharma companies look to broaden their suite of therapies via acquisitions. Bristol-Myers is planning to tender its shares in <a href=\"https://laohu8.com/S/XLRN\">Acceleron Pharma Inc.</a> after Merck &amp; Co. agreed to buy the biotechnology company for $11.5 billion, Bloomberg News reported this week.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-23 10:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to people familiar with the matter.\nThe New ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2177414750","content_text":"(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to people familiar with the matter.\nThe New York-based company recently approached Aurinia about a deal, said the people, who asked to not be identified because the matter isn’t public. No final decision has been made and Bristol-Myers could opt against any potential deal, they said.\nAurinia rose 27% to close at $28.00 in New York on Friday, giving the company a market value of about $3.6 billion.\nA spokesperson for Bristol Myers said the company wouldn’t comment on rumors. A representative for Aurinia declined to comment.\nFormally known as Isotechnika Pharma, Aurinia specializes in therapies for severe autoimmune diseases, according to its website. It recently introduced an oral therapy for adults with lupus nephritis, a kidney disorder.\nThe talks come during a boom in health-care dealmaking, as large pharma companies look to broaden their suite of therapies via acquisitions. Bristol-Myers is planning to tender its shares in Acceleron Pharma Inc. after Merck & Co. agreed to buy the biotechnology company for $11.5 billion, Bloomberg News reported this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6310093,"gmtCreate":1635088808649,"gmtModify":1635088808679,"authorId":3581939971426189,"author":{"id":3581939971426189,"idStr":"3581939971426189","authorId":3581939971426189,"name":"pokokoko","avatar":"https://static.tigerbbs.com/a2ecfa72bfcaf6497e5b5a50fa2b1fe7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":858558559,"type":1,"supId":0,"prevId":0,"content":"<u>up</u>","text":"<u>up</u>","html":"<u>up</u>"}],"langContent":"CN"},{"id":858637520,"gmtCreate":1635043216311,"gmtModify":1635043217237,"author":{"id":"3576363559636103","authorId":"3576363559636103","name":"LimHianYew","avatar":"https://static.tigerbbs.com/6d37a520eb4e35950b060938ddb5e317","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3576363559636103","idStr":"3576363559636103"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/858637520","repostId":2177414750,"repostType":4,"repost":{"id":"2177414750","pubTimestamp":1634955009,"share":"https://www.laohu8.com/m/news/2177414750?lang=&edition=full","pubTime":"2021-10-23 10:10","market":"us","language":"en","title":"Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2177414750","media":"Bloomberg","summary":"(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmac","content":"<p>(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm <a href=\"https://laohu8.com/S/AUPH\">Aurinia Pharmaceuticals Inc</a>., according to people familiar with the matter.</p>\n<p>The New York-based company recently approached Aurinia about a deal, said the people, who asked to not be identified because the matter isn’t public. No final decision has been made and Bristol-Myers could opt against any potential deal, they said.</p>\n<p>Aurinia rose 27% to close at $28.00 in New York on Friday, giving the company a market value of about $3.6 billion.</p>\n<p>A spokesperson for Bristol Myers said the company wouldn’t comment on rumors. A representative for Aurinia declined to comment.</p>\n<p>Formally known as Isotechnika Pharma, Aurinia specializes in therapies for severe autoimmune diseases, according to its website. It recently introduced an oral therapy for adults with lupus nephritis, a kidney disorder.</p>\n<p>The talks come during a boom in health-care dealmaking, as large pharma companies look to broaden their suite of therapies via acquisitions. Bristol-Myers is planning to tender its shares in <a href=\"https://laohu8.com/S/XLRN\">Acceleron Pharma Inc.</a> after Merck &amp; Co. agreed to buy the biotechnology company for $11.5 billion, Bloomberg News reported this week.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-23 10:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to people familiar with the matter.\nThe New ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2177414750","content_text":"(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to people familiar with the matter.\nThe New York-based company recently approached Aurinia about a deal, said the people, who asked to not be identified because the matter isn’t public. No final decision has been made and Bristol-Myers could opt against any potential deal, they said.\nAurinia rose 27% to close at $28.00 in New York on Friday, giving the company a market value of about $3.6 billion.\nA spokesperson for Bristol Myers said the company wouldn’t comment on rumors. A representative for Aurinia declined to comment.\nFormally known as Isotechnika Pharma, Aurinia specializes in therapies for severe autoimmune diseases, according to its website. It recently introduced an oral therapy for adults with lupus nephritis, a kidney disorder.\nThe talks come during a boom in health-care dealmaking, as large pharma companies look to broaden their suite of therapies via acquisitions. Bristol-Myers is planning to tender its shares in Acceleron Pharma Inc. after Merck & Co. agreed to buy the biotechnology company for $11.5 billion, Bloomberg News reported this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":858886269,"gmtCreate":1635036119597,"gmtModify":1635036120204,"author":{"id":"4096716579918630","authorId":"4096716579918630","name":"LerLer","avatar":"https://static.tigerbbs.com/5d9c27b1b7f5511be5a9e126e20e198f","vip":1,"hat":"https://static.tigerbbs.com/48729dafeca47ea4d9d9218d85913fd4","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4096716579918630","idStr":"4096716579918630"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/858886269","repostId":2177414750,"repostType":4,"repost":{"id":"2177414750","pubTimestamp":1634955009,"share":"https://www.laohu8.com/m/news/2177414750?lang=&edition=full","pubTime":"2021-10-23 10:10","market":"us","language":"en","title":"Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2177414750","media":"Bloomberg","summary":"(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmac","content":"<p>(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm <a href=\"https://laohu8.com/S/AUPH\">Aurinia Pharmaceuticals Inc</a>., according to people familiar with the matter.</p>\n<p>The New York-based company recently approached Aurinia about a deal, said the people, who asked to not be identified because the matter isn’t public. No final decision has been made and Bristol-Myers could opt against any potential deal, they said.</p>\n<p>Aurinia rose 27% to close at $28.00 in New York on Friday, giving the company a market value of about $3.6 billion.</p>\n<p>A spokesperson for Bristol Myers said the company wouldn’t comment on rumors. A representative for Aurinia declined to comment.</p>\n<p>Formally known as Isotechnika Pharma, Aurinia specializes in therapies for severe autoimmune diseases, according to its website. It recently introduced an oral therapy for adults with lupus nephritis, a kidney disorder.</p>\n<p>The talks come during a boom in health-care dealmaking, as large pharma companies look to broaden their suite of therapies via acquisitions. Bristol-Myers is planning to tender its shares in <a href=\"https://laohu8.com/S/XLRN\">Acceleron Pharma Inc.</a> after Merck &amp; Co. agreed to buy the biotechnology company for $11.5 billion, Bloomberg News reported this week.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-23 10:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to people familiar with the matter.\nThe New ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2177414750","content_text":"(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to people familiar with the matter.\nThe New York-based company recently approached Aurinia about a deal, said the people, who asked to not be identified because the matter isn’t public. No final decision has been made and Bristol-Myers could opt against any potential deal, they said.\nAurinia rose 27% to close at $28.00 in New York on Friday, giving the company a market value of about $3.6 billion.\nA spokesperson for Bristol Myers said the company wouldn’t comment on rumors. A representative for Aurinia declined to comment.\nFormally known as Isotechnika Pharma, Aurinia specializes in therapies for severe autoimmune diseases, according to its website. It recently introduced an oral therapy for adults with lupus nephritis, a kidney disorder.\nThe talks come during a boom in health-care dealmaking, as large pharma companies look to broaden their suite of therapies via acquisitions. Bristol-Myers is planning to tender its shares in Acceleron Pharma Inc. after Merck & Co. agreed to buy the biotechnology company for $11.5 billion, Bloomberg News reported this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6305262,"gmtCreate":1635043229365,"gmtModify":1635043229406,"authorId":3576363559636103,"author":{"id":3576363559636103,"idStr":"3576363559636103","authorId":3576363559636103,"name":"LimHianYew","avatar":"https://static.tigerbbs.com/6d37a520eb4e35950b060938ddb5e317","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":858886269,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":6304664,"gmtCreate":1635040981881,"gmtModify":1635040982000,"authorId":3580766516032125,"author":{"id":3580766516032125,"idStr":"3580766516032125","authorId":3580766516032125,"name":"JooL","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":858886269,"type":1,"supId":0,"prevId":0,"content":"😄","text":"😄","html":"😄"}],"langContent":"CN"},{"id":858816145,"gmtCreate":1635035051029,"gmtModify":1635035061180,"author":{"id":"3581854803062408","authorId":"3581854803062408","name":"supergrowth","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581854803062408","idStr":"3581854803062408"},"htmlText":"Good dividend. Withholding tax is reduce dividend☹","listText":"Good dividend. Withholding tax is reduce dividend☹","text":"Good dividend. Withholding tax is reduce dividend☹","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/858816145","repostId":2177414750,"repostType":4,"repost":{"id":"2177414750","pubTimestamp":1634955009,"share":"https://www.laohu8.com/m/news/2177414750?lang=&edition=full","pubTime":"2021-10-23 10:10","market":"us","language":"en","title":"Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2177414750","media":"Bloomberg","summary":"(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmac","content":"<p>(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm <a href=\"https://laohu8.com/S/AUPH\">Aurinia Pharmaceuticals Inc</a>., according to people familiar with the matter.</p>\n<p>The New York-based company recently approached Aurinia about a deal, said the people, who asked to not be identified because the matter isn’t public. No final decision has been made and Bristol-Myers could opt against any potential deal, they said.</p>\n<p>Aurinia rose 27% to close at $28.00 in New York on Friday, giving the company a market value of about $3.6 billion.</p>\n<p>A spokesperson for Bristol Myers said the company wouldn’t comment on rumors. A representative for Aurinia declined to comment.</p>\n<p>Formally known as Isotechnika Pharma, Aurinia specializes in therapies for severe autoimmune diseases, according to its website. It recently introduced an oral therapy for adults with lupus nephritis, a kidney disorder.</p>\n<p>The talks come during a boom in health-care dealmaking, as large pharma companies look to broaden their suite of therapies via acquisitions. Bristol-Myers is planning to tender its shares in <a href=\"https://laohu8.com/S/XLRN\">Acceleron Pharma Inc.</a> after Merck &amp; Co. agreed to buy the biotechnology company for $11.5 billion, Bloomberg News reported this week.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-23 10:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to people familiar with the matter.\nThe New ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2177414750","content_text":"(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to people familiar with the matter.\nThe New York-based company recently approached Aurinia about a deal, said the people, who asked to not be identified because the matter isn’t public. No final decision has been made and Bristol-Myers could opt against any potential deal, they said.\nAurinia rose 27% to close at $28.00 in New York on Friday, giving the company a market value of about $3.6 billion.\nA spokesperson for Bristol Myers said the company wouldn’t comment on rumors. A representative for Aurinia declined to comment.\nFormally known as Isotechnika Pharma, Aurinia specializes in therapies for severe autoimmune diseases, according to its website. It recently introduced an oral therapy for adults with lupus nephritis, a kidney disorder.\nThe talks come during a boom in health-care dealmaking, as large pharma companies look to broaden their suite of therapies via acquisitions. Bristol-Myers is planning to tender its shares in Acceleron Pharma Inc. after Merck & Co. agreed to buy the biotechnology company for $11.5 billion, Bloomberg News reported this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":858818284,"gmtCreate":1635035017294,"gmtModify":1635035017944,"author":{"id":"3582248650466523","authorId":"3582248650466523","name":"Victorhc88","avatar":"https://static.tigerbbs.com/d72a1d9498132424b1eddb4db3c77265","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3582248650466523","idStr":"3582248650466523"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/858818284","repostId":2177414750,"repostType":4,"repost":{"id":"2177414750","pubTimestamp":1634955009,"share":"https://www.laohu8.com/m/news/2177414750?lang=&edition=full","pubTime":"2021-10-23 10:10","market":"us","language":"en","title":"Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2177414750","media":"Bloomberg","summary":"(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmac","content":"<p>(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm <a href=\"https://laohu8.com/S/AUPH\">Aurinia Pharmaceuticals Inc</a>., according to people familiar with the matter.</p>\n<p>The New York-based company recently approached Aurinia about a deal, said the people, who asked to not be identified because the matter isn’t public. No final decision has been made and Bristol-Myers could opt against any potential deal, they said.</p>\n<p>Aurinia rose 27% to close at $28.00 in New York on Friday, giving the company a market value of about $3.6 billion.</p>\n<p>A spokesperson for Bristol Myers said the company wouldn’t comment on rumors. A representative for Aurinia declined to comment.</p>\n<p>Formally known as Isotechnika Pharma, Aurinia specializes in therapies for severe autoimmune diseases, according to its website. It recently introduced an oral therapy for adults with lupus nephritis, a kidney disorder.</p>\n<p>The talks come during a boom in health-care dealmaking, as large pharma companies look to broaden their suite of therapies via acquisitions. Bristol-Myers is planning to tender its shares in <a href=\"https://laohu8.com/S/XLRN\">Acceleron Pharma Inc.</a> after Merck &amp; Co. agreed to buy the biotechnology company for $11.5 billion, Bloomberg News reported this week.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-23 10:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to people familiar with the matter.\nThe New ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2177414750","content_text":"(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to people familiar with the matter.\nThe New York-based company recently approached Aurinia about a deal, said the people, who asked to not be identified because the matter isn’t public. No final decision has been made and Bristol-Myers could opt against any potential deal, they said.\nAurinia rose 27% to close at $28.00 in New York on Friday, giving the company a market value of about $3.6 billion.\nA spokesperson for Bristol Myers said the company wouldn’t comment on rumors. A representative for Aurinia declined to comment.\nFormally known as Isotechnika Pharma, Aurinia specializes in therapies for severe autoimmune diseases, according to its website. It recently introduced an oral therapy for adults with lupus nephritis, a kidney disorder.\nThe talks come during a boom in health-care dealmaking, as large pharma companies look to broaden their suite of therapies via acquisitions. Bristol-Myers is planning to tender its shares in Acceleron Pharma Inc. after Merck & Co. agreed to buy the biotechnology company for $11.5 billion, Bloomberg News reported this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":858838417,"gmtCreate":1635034171601,"gmtModify":1635034172812,"author":{"id":"3579641974902127","authorId":"3579641974902127","name":"ivy888","avatar":"https://static.tigerbbs.com/10358949b7fc96b011ec29ca7fd9c9a4","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3579641974902127","idStr":"3579641974902127"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/858838417","repostId":2177414750,"repostType":4,"repost":{"id":"2177414750","pubTimestamp":1634955009,"share":"https://www.laohu8.com/m/news/2177414750?lang=&edition=full","pubTime":"2021-10-23 10:10","market":"us","language":"en","title":"Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2177414750","media":"Bloomberg","summary":"(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmac","content":"<p>(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm <a href=\"https://laohu8.com/S/AUPH\">Aurinia Pharmaceuticals Inc</a>., according to people familiar with the matter.</p>\n<p>The New York-based company recently approached Aurinia about a deal, said the people, who asked to not be identified because the matter isn’t public. No final decision has been made and Bristol-Myers could opt against any potential deal, they said.</p>\n<p>Aurinia rose 27% to close at $28.00 in New York on Friday, giving the company a market value of about $3.6 billion.</p>\n<p>A spokesperson for Bristol Myers said the company wouldn’t comment on rumors. A representative for Aurinia declined to comment.</p>\n<p>Formally known as Isotechnika Pharma, Aurinia specializes in therapies for severe autoimmune diseases, according to its website. It recently introduced an oral therapy for adults with lupus nephritis, a kidney disorder.</p>\n<p>The talks come during a boom in health-care dealmaking, as large pharma companies look to broaden their suite of therapies via acquisitions. Bristol-Myers is planning to tender its shares in <a href=\"https://laohu8.com/S/XLRN\">Acceleron Pharma Inc.</a> after Merck &amp; Co. agreed to buy the biotechnology company for $11.5 billion, Bloomberg News reported this week.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-23 10:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to people familiar with the matter.\nThe New ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/bristol-myers-makes-takeover-approach-201110389.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2177414750","content_text":"(Bloomberg) -- Bristol-Myers Squibb Co. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc., according to people familiar with the matter.\nThe New York-based company recently approached Aurinia about a deal, said the people, who asked to not be identified because the matter isn’t public. No final decision has been made and Bristol-Myers could opt against any potential deal, they said.\nAurinia rose 27% to close at $28.00 in New York on Friday, giving the company a market value of about $3.6 billion.\nA spokesperson for Bristol Myers said the company wouldn’t comment on rumors. A representative for Aurinia declined to comment.\nFormally known as Isotechnika Pharma, Aurinia specializes in therapies for severe autoimmune diseases, according to its website. It recently introduced an oral therapy for adults with lupus nephritis, a kidney disorder.\nThe talks come during a boom in health-care dealmaking, as large pharma companies look to broaden their suite of therapies via acquisitions. Bristol-Myers is planning to tender its shares in Acceleron Pharma Inc. after Merck & Co. agreed to buy the biotechnology company for $11.5 billion, Bloomberg News reported this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6303355,"gmtCreate":1635034985846,"gmtModify":1635034985889,"authorId":3581854803062408,"author":{"id":3581854803062408,"idStr":"3581854803062408","authorId":3581854803062408,"name":"supergrowth","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":858838417,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":881,"commentSize":56,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2177414750"}